Search the Newsreel

Should Willdan’s US$31 Million Wastewater Biogas Deal Reshape How WLDN Investors View Its Growth Path?

Willdan Group, Inc. has secured a US$31 million design-build contract with Encina Wastewater Authority for a renewable cogeneration project. This deal, along with a recent US$112 million contract with the City of San Diego, reinforces Willdan's expertise in distributed energy and microgrid projects, potentially …

Is Lloyds Banking Group (LSE:LLOY) Still Cheap After Rule Relief?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Lloyds Banking Group has delivered very strong share price gains over the past few years, yet its valuation checks are sending mixed signals, …

Celldex CFO Sam Martin to Retire; Company Begins Search for Successor

Celldex Senior Vice President and Chief Financial Officer Sam Martin announced his retirement, effective on or about March 31, 2027. The company has initiated a search for his successor. Martin joined Celldex in April 2009 and has served as CFO since July 2017.

Willdan Selected by Encina Wastewater Authority for $31 Million Cogeneration Project

Willdan Group, Inc. has been awarded a $31 million design-build contract by the Encina Wastewater Authority to develop a renewable cogeneration project. This initiative will convert wastewater-generated biogas into on-site electricity, bolstering resilient plant operations and significantly reducing emissions. The project aims to meet …

Celldex Starts CFO Search as Martin Plans 2027 Retirement

Celldex (NASDAQ:CLDX) announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire in March 2027. Martin, who has served as CFO since 2017 and has been with Celldex since 2009, will remain in his role during the search for …

Celldex CFO Sam Martin to retire in March 2027 By Investing.com

Sam Martin, Celldex Therapeutics' Senior Vice President and Chief Financial Officer, announced his retirement effective March 2027. Martin has been with the company's finance team since 2009 and served as CFO since 2017, overseeing a period of strong financial health. Celldex, which develops antibody-based …

Celldex Announces Planned Transition of Chief Financial Officer

Celldex announced that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire in 2027. Mr. Martin, who has been with Celldex since 2009 and CFO since 2017, will remain in his role until March 2027 to ensure a smooth transition while …

Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027

Celldex Therapeutics announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire around March 31, 2027. Martin, who has been with the company since 2009 and CFO since 2017, will remain in his role until his successor is appointed …

Willdan wins $31 million wastewater energy project contract

Willdan Group Inc. (NASDAQ:WLDN) has secured a $31 million design-build contract from Encina Wastewater Authority for a renewable cogeneration project in Carlsbad, California. This project will convert biogas from wastewater treatment into on-site electricity, supporting plant operations and reducing emissions. The contract contributes to …

Wastewater biogas project aims to power 100% of Encina's needs

Willdan Group, Inc. has been awarded a $31 million design-build contract by Encina Wastewater Authority for a renewable cogeneration project. This project will utilize biogas from wastewater treatment to generate on-site electricity, aiming to meet 100% of Encina's electrical needs and ensure resilient operations …

Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027

Celldex Therapeutics, Inc. announced that Sam Martin, their Senior Vice President and Chief Financial Officer, plans to retire around March 31, 2027. Martin has been with Celldex since 2009 and served as CFO since 2017. The company has initiated a search for his successor, …

Willdan Group Seen Being Net Beneficiary of Grid Infrastructure Buildout Despite Negative Sentiment, Wedbush Says

Wedbush analysts believe Willdan Group (WLDN) is poised to be a net beneficiary of the ongoing grid infrastructure buildout, despite current negative market sentiment. The firm initiated coverage on WLDN with an Outperform rating and a $30 price target, highlighting the company's strong potential …

Celldex Therapeutics, Inc. Actuals & Estimates (NASDAQ:CLDX)

CLDX Forecast — Price Target — Prediction for 2027

CLDX Q1 2026 Earnings: Celldex Reports EPS Miss Amid Early-Stage Pipeline Progress - Forward Guidance Trends

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next

Celldex Therapeutics (CLDX) Stock Price, News & Analysis

Lloyds Banking Group plc Aktie | Kurs | Dividende | Nachrichten (871784, GB0008706128)

Celldex Therapeutics Inc. (CLDX) News, Articles, Events & Latest Updates

Lloyds Banking Group plc: Konsensus der Analysten und Kursziel | 871784 | GB0008706128

Lloyds Banking Group Aktie: Aktienkurs & Charts

Lloyds Banking Group Aktie • 871784 • GB0008706128

Celldex Therapeutics, Inc. (CLDX) Stock Price, News, Quote & History